395 related articles for article (PubMed ID: 25122578)
1. Antiretroviral treatment failure predicts mortality in rural Tanzania.
Pettersen PS; Brox IK; Naman E; Bruun JN; Dyrhol-Riise AM; Trøseid M; Johannessen A
Int J STD AIDS; 2015 Aug; 26(9):633-9. PubMed ID: 25122578
[TBL] [Abstract][Full Text] [Related]
2. Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression.
Ntamatungiro AJ; Muri L; Glass TR; Erb S; Battegay M; Furrer H; Hatz C; Tanner M; Felger I; Klimkait T; Letang E;
J Antimicrob Chemother; 2017 Jul; 72(7):2069-2074. PubMed ID: 28387865
[TBL] [Abstract][Full Text] [Related]
3. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
[TBL] [Abstract][Full Text] [Related]
4. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China.
Wang J; Wang Z; Liu J; Yue Y; Yang S; Huang H; He C; Liao L; Xing H; Ruan Y; Shao Y
Sci Rep; 2015 Oct; 5():14823. PubMed ID: 26445885
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 drug resistance at virological failure versus immunological failure among patients failing first-line antiretroviral therapy in a resource-limited setting.
Sungkanuparph S; Win MM; Kiertiburanakul S; Phonrat B; Maek-a-nantawat W
Int J STD AIDS; 2012 May; 23(5):316-8. PubMed ID: 22648883
[TBL] [Abstract][Full Text] [Related]
7. A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.
Marcelin AG; Delaugerre C; Beaudoux C; Descamps D; Morand-Joubert L; Amiel C; Schneider V; Ferre V; Izopet J; Si-Mohamed A; Maillard A; Henquell C; Desbois D; Lazrek M; Signori-Schmuck A; Rogez S; Yerly S; Trabaud MA; Plantier JC; Fourati S; Houssaini A; Masquelier B; Calvez V; Flandre P;
Int J Antimicrob Agents; 2013 Jul; 42(1):42-7. PubMed ID: 23562640
[TBL] [Abstract][Full Text] [Related]
8. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
[TBL] [Abstract][Full Text] [Related]
9. Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa.
Schoffelen AF; Wensing AM; Tempelman HA; Geelen SP; Hoepelman AI; Barth RE
PLoS One; 2013; 8(3):e58526. PubMed ID: 23505529
[TBL] [Abstract][Full Text] [Related]
10. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
Pernas B; Grandal M; Pertega S; Cañizares A; Castro-Iglesias Á; Mena Á; Rodriguez-Osorio I; Tabernilla A; Pedreira JD; Poveda E
J Antimicrob Chemother; 2016 Apr; 71(4):1051-5. PubMed ID: 26702924
[TBL] [Abstract][Full Text] [Related]
11. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
[TBL] [Abstract][Full Text] [Related]
12. Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy.
Silveira MP; Silveira CP; Guttier MC; Page K; Moreira LB
J Clin Pharm Ther; 2016 Dec; 41(6):689-694. PubMed ID: 27676134
[TBL] [Abstract][Full Text] [Related]
13. Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.
Byakwaga H; Murray JM; Petoumenos K; Kelleher AD; Law MG; Boyd MA; Emery S; Mallon PW; Cooper DA
AIDS Res Hum Retroviruses; 2009 Jun; 25(6):756-76. PubMed ID: 19500017
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
Clevenbergh P; Boulmé R; Kirstetter M; Dellamonica P
HIV Med; 2004 Jul; 5(4):284-8. PubMed ID: 15236618
[TBL] [Abstract][Full Text] [Related]
17. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon .
Zoufaly A; Jochum J; Hammerl R; Nassimi N; Raymond Y; Burchard GD; Schmiedel S; Drexler JF; Campbell NK; Taka N; Awasom C; Metzner KJ; van Lunzen J; Feldt T
J Antimicrob Chemother; 2015 Mar; 70(3):922-5. PubMed ID: 25428920
[TBL] [Abstract][Full Text] [Related]
18. Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort.
Zolfo M; Schapiro JM; Phan V; Koole O; Thai S; Vekemans M; Fransen K; Lynen L
AIDS Res Hum Retroviruses; 2011 Jul; 27(7):727-35. PubMed ID: 20854169
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
[TBL] [Abstract][Full Text] [Related]
20. Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes?
Orrell C; Cohen K; Leisegang R; Bangsberg DR; Wood R; Maartens G
AIDS Res Ther; 2017 Apr; 14(1):20. PubMed ID: 28376815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
